Metabolism drugs are used to treat metabolic disorders such as diabetes, dyslipidemia, obesity, and related conditions. These drugs help regulate and assist metabolic processes in the body through various mechanisms of action including increasing insulin secretion and sensitivity, inhibiting glucose absorption in the intestines, blocking fat absorption, increasing fat metabolism, and suppressing appetite.
The global Metabolism Drugs Market is estimated to be valued at Us$ 9410.88 Mn in 2023 and is expected to exhibit a CAGR Of 2.3% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing prevalence of metabolic disorders such as diabetes and obesity globally is expected to drive the growth of metabolism drugs market over the forecast period. According to International Diabetes Federation, approximately 643 million adults were living with diabetes in 2023 with the number expected to rise to 783 million by 2045. Additionally, rising prevalence of obesity is also fueling the demand for metabolism drugs for weight management. As per the data by WHO, in 2022, around 13% of adults aged 18 years and older were obese globally. One of the key drivers propelling the growth of metabolism drugs is increasing R&D investments by leading players for development of novel and efficacious drug molecules.
SWOT Analysis
Strength: Metabolism drugs help regulate and balance body metabolism. They can treat various metabolic disorders like diabetes, obesity effectively. New drug formulations make these drugs easy to consume and absorb in the body.
Weakness: Metabolism drugs sometimes cause undesirable side effects like nausea, vomiting, allergy and rashes if not taken as prescribed. Developing new drugs involves huge investments and long research timelines. FDA approvals for new drugs are stringent and lengthy.
Opportunity: Rising incidence of lifestyle diseases and obesity worldwide is increasing the demand for metabolism regulating drugs. Growing geriatric population prone to age-related metabolic disorders boost the market. Advances in drug delivery technologies offer new opportunities.
Threats: Alternative therapies like herbal medicines, dietary changes pose competition. Patent expiries of blockbuster drugs impact revenues of producers. Stringent regulations and price controls by governments affect profit margins.
Key Takeaways
The Global Metabolism Drugs Market Size is expected to witness high growth. The global metabolism drugs market is estimated to be valued at US$ 9410.88 Mn in 2023 and is expected to exhibit a CAGR of 2.3% over the forecast period 2024-2031.
North America currently dominates due to growing obesity, presence of key players and heavy investments in R&D. However, Asia Pacific is expected to be the fastest growing region owing to increasing healthcare spending, large patient pool and growing medical tourism.
Key players operating in the Metabolism Drugs market are 3M, Amgen, Astra Zeneca, Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KGaA and Novartis AG. These companies are focusing on developing new formulations and drug delivery mechanisms to strengthen their market presence.
Get more insights on this topic :
Check more trending articles on this topic:
https://techaxen.com/medicine-testing-services-in-the-us-ensuring-product-safety-and-compliance/
Romaian
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek